Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pf-04937319 | Drug | Formulation A) Pf-04937319 50 mg - administered as tablet | ||
| Pf-04937319 | Drug | Formulation B) Pf-04937319 50 mg - administered as capsule | ||
| Pf-04937319 | Drug | Formulation C) Pf-04937319 50 mg - administered as capsule |
| Measure | Description | Time Frame |
|---|---|---|
| Pf-04937319: Maximum plasma concentration (Cmax) | 0 - 96 hours post dose | |
| Pf-04937319: Time for Cmax (Tmax) | 0 - 96 hours post dose | |
| Pf-04937319: Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (AUClast) | 0 - 96 hours post dose | |
| Pf-04937319: Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf) | 0 - 96 hours post dose | |
| Pf-04937319: terminal half-life (T1/2) | 0 - 96 hours post dose | |
| PF-06455349: Maximum Observed Plasma Concentration (Cmax) | 0 - 96 hours post dose | |
| PF-06455349: Time to Reach Maximum Observed Plasma Concentration (Tmax) | 0 - 96 hours post dose | |
| PF-06455349: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) | 0 - 96 hours post dose | |
| PF-06455349: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] | 0 - 96 hours post dose | |
| PF-06455349: Plasma Decay Half-Life (t1/2) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Singapore | Singapore | 188770 | Singapore |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C000598526 | N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 0 - 96 hours post dose |